India Markets closed

Aleafia Health Inc. (ALEAF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.6416-0.0184 (-2.79%)
At close: 3:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.6600
Open0.7000
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.6400 - 0.7000
52-week range0.1990 - 0.7000
Volume620,812
Avg. volume307,768
Market cap195.306M
Beta (5Y monthly)1.58
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Aleafia Health Launches Portfolio of Exclusive Cultivars
    GlobeNewswire

    Aleafia Health Launches Portfolio of Exclusive Cultivars

    Aleafia Health Exclusive Cultivars Launch Wedding Cake * Highly sought-after strain Wedding Cake available today * BLLRDR is majority-owned by two-time GRAMMY Award winning producer Noah “40” Shebib and original Emblem co-founder Max Zavet * Additional near-term expansion of product portfolio with launch of new cannabis 2.0 formats and dried flower in Q1 2021 * Product launches key accelerator in driving record revenue in Q4 2020TORONTO, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the launch of its portfolio of exclusive cannabis cultivars with highly sought-after strain Wedding Cake. In the Canadian medical cannabis market, it is exclusively available through Emblem Cannabis Corporation, a wholly-owned subsidiary of Aleafia Health.Wedding Cake is licensed through a supply agreement with cannabis brand house Robes Cannabis Inc. (dba BLLRDR). GRAMMY Award winning producer and OVO co-founder, Noah “40” Shebib, and Emblem co-founder Max Zavet are BLLRDR’s majority owners.The launch is part of a broader expansion of the Company’s portfolio of unique cannabis cultivars which will see further strains to enter the adult-use and medical cannabis markets this year.“The introduction of new products continues to be our most important accelerator in driving further growth in the Canadian market. Today’s launch allows us to strengthen our unique medical patient experience, featuring differentiated formats, physician-led cannabinoid therapy, and same-day delivery,” said Aleafia Health CEO Geoffrey Benic. “We look forward to delivering on further innovative product launches this quarter and throughout 2021.”For Investor & Media Relations: Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com LEARN MORE: www.AleafiaHealth.comAbout Aleafia Health:Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.Forward Looking InformationThis news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/90310d67-1cc0-411e-b872-777494d85eb9

  • Aleafia Health Enters Definitive Supply Agreement with European Pharmaceutical Producer Apipharm
    GlobeNewswire

    Aleafia Health Enters Definitive Supply Agreement with European Pharmaceutical Producer Apipharm

    * New international agreement strengthens Aleafia Health’s global distribution network * Initial purchase order for 1,000 kg of dried cannabis flower, with fulfilment of order underway * Apipharm a leading European natural pharmaceutical company with distribution in nine countriesTORONTO, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) has entered into a definitive three-year cannabis supply agreement (the “Supply Agreement”) with Apipharm Veletrgovina d.o.o. (“Apipharm”) a leading European pharmaceutical producer and distributor.Apipharm specializes in the distribution of active pharmaceutical ingredients of plant origin including semi-synthetic cannabinoid isolates, along with the development of advanced pharmaceutical formulations.Under the terms of the agreement, Aleafia Health will supply Apipharm with dried cannabis flower grown at its Niagara greenhouse facility. Apipharm has also submitted an initial purchase order to Aleafia Health, for 1,000 kg of premium dried flower. The initial purchase order is expected to ship as early as the end of Q1 2021, dependent on the timing of necessary import and export permits.“It is our great pleasure that we have entered into a partnership agreement with Aleafia which will strengthen our market position in the development of advanced pharmaceutical formulations,” said Dr. Matevz Pompe, CEO of Apiharm.“We are delighted to open a new international sales channel leveraging the well-established distribution network and expertise of Apipharm,” said Aleafia Health CEO Geoffrey Benic. “Building on our best results to date in the most recent quarter, we will continue to execute on near-term international sales opportunities, fully leveraging our world class Canadian cannabis production assets.”Aleafia Health Contact:Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com www.AleafiaHealth.comApipharm Contact:Dr. Matevz Pompe, CEO +386 51 618 182 matevz.pompe@apipharm.si www.apipharm.siAbout Aleafia Health:Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.Forward Looking InformationThis news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

  • Aleafia Health Announces Intention to Repay $25M Convertible Debenture with Cash
    GlobeNewswire

    Aleafia Health Announces Intention to Repay $25M Convertible Debenture with Cash

    * Repayment provides greater operational flexibility to build on record cannabis revenue realized in Q4 2020 * Results in $2M reduction in annual interest paymentsTORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce its intention to repay in cash its 8% unsecured convertible debt (the “Convertible Debt”) which matures on February 2, 2021. The Convertible Debt was issued by Emblem Corp. on February 2, 2018, and Emblem was acquired by the Company on March 14, 2019.The Company currently has no materially significant senior secured debt, and its facilities are fully unencumbered, providing further flexibility for additional financing if necessary. The repayment will result in a $2 million reduction in annual interest expenses.“Through continued fiscal discipline over the course of 2020 and our focus on sustainable growth, we are in a position to eliminate near-term debt. We believe that this approach benefits shareholders and clears the path for continued growth in 2021,” said Aleafia Health CEO Geoffrey Benic.“The path we’ve taken is now delivering clear results, achieving record cannabis revenue in our recently completed fourth quarter. We look forward to building on the quarter’s robust sales growth across every cannabis sales channel, including domestic medical, adult-use, wholesale, and international.”For Investor & Media Relations:Nicholas Bergamini, VP Investor Relations 1-833-879-2533 IR@AleafiaHealth.com LEARN MORE: www.AleafiaHealth.comAbout Aleafia Health:Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets. The Company operates medical clinics, education centres and production facilities for the production and sale of cannabis.Aleafia Health owns three significant licensed cannabis production facilities, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of commercially proven, high-margin derivative products including oils, capsules and sprays. Aleafia Health operates the largest national network of medical cannabis clinics and education centres staffed by MDs, nurse practitioners and educators and operates internationally in three continents.Innovation, the heart of Aleafia Health’s competitive advantage, has led to the Company maintaining a medical cannabis dataset with over 10 million data points to inform proprietary illness-specific product development and its highly differentiated education platform FoliEdge Academy. The Company is committed to creating sustainable shareholder value; the TSX Venture Exchange named Aleafia the 2019 top performing company prior to its graduation to the TSX.Forward Looking InformationThis news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.